Quantcast

Latest Lorcaserin Stories

2010-05-07 06:30:00

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the first quarter ended March 31, 2010. Arena reported a lower net loss in the first quarter of 2010 of $31.3 million, or $0.33 per share, compared to a net loss in the first quarter of 2009 of $50.6 million, or $0.68 per share. "We believe that lorcaserin represents a significant medical and commercial opportunity based on the drug candidate's unique combination of...

2010-05-06 07:00:00

SAN DIEGO, May 6, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Ninth Annual JMP Securities Research Conference on Tuesday, May 11, 2010, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) at The Ritz-Carlton in San Francisco. Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, is scheduled to provide an overview of the company, including its clinical development and...

2010-04-30 07:00:00

SAN DIEGO, April 30, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report first quarter 2010 financial results before the NASDAQ Global Market opens on Friday, May 7, 2010. That same morning, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial...

2010-04-28 07:00:00

SAN DIEGO, April 28, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Deutsche Bank 35th Annual Health Care Conference on Monday, May 3, 2010, at 11:20 a.m. Eastern Time (8:20 a.m. Pacific Time) at the InterContinental Boston Hotel in Boston. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery...

2010-03-24 07:00:00

SAN DIEGO, March 24, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy. "There is a need for better tolerated, more effective therapies for narcolepsy, especially narcolepsy with cataplexy," said William R. Shanahan, M.D., Arena's Vice President...

2010-03-18 07:00:00

SAN DIEGO, March 18, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010, at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) at the Loews Miami Beach Hotel in Miami, Florida. Cindy McGee, Arena's Manager of Investor Relations and Corporate Communications, is scheduled to provide an overview of the company, including its clinical...

2010-03-12 06:30:00

SAN DIEGO, March 12, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2009. Arena reported a lower net loss allocable to common stockholders in the fourth quarter of 2009 of $29.8 million, or $0.32 per share, compared to a net loss allocable to common stockholders in the fourth quarter of 2008 of $62.5 million, or $0.84 per share, and a net loss allocable to common...

2010-03-08 15:00:00

SAN DIEGO, March 8, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Cowen and Company 30th Annual Health Care Conference on Wednesday, March 10, 2010, at 8:45 a.m. Eastern Time (5:45 a.m. Pacific Time) at the Boston Marriott Copley Place in Boston, Massachusetts. Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, is scheduled to provide an overview of the company,...

2010-03-08 07:00:00

SAN DIEGO, March 8, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2009 financial results before the NASDAQ Global Market opens on Friday, March 12, 2010. That same morning, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss...

2010-02-26 07:00:00

SAN DIEGO, Feb. 26, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2010, for the review of the lorcaserin New Drug Application (NDA). The acceptance of the lorcaserin NDA filing confirms that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for the FDA to complete its...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related